TNFSF11 and chronic kidney disease: Small clinical trials utilizing denosumab, an antibody against RANKL, have shown reduced markers of bone turnover,17 reduction in fracture risk,43 and generally similar safety and efficacy in patients with mild and moderate CKD compared to those without CKD.18